Every material Form 8-K Indaptus Therapeutics, Inc. has filed with the SEC since September 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Indaptus Therapeutics said it completed a private placement on October 16, 2026, after receiving the full purchase price from each purchaser under the purchase agreement, as amended. The company will issue an aggregate of 20,338,974 shares to the purchasers, which adds to the number of shares outstanding. The filing does not state the total proceeds or price per share.
Private placement closed on October 16, 2026, with full purchase price received from each purchaser.
Company will issue an aggregate of 20,338,974 shares to the purchasers.
The filing does not disclose the total proceeds or the price per share.
Indaptus Therapeutics agreed on September 29, 2026 to extend the outside date for the closing of its $24.0 million private placement of common stock from September 29 to October 16, 2026. The notices and consents also let the company defer closing until purchaser closing conditions are met or waived, and extend the purchasers' funding deadline and related termination rights to the same date. For shareholders, the filing shows the financing has not yet closed and its timing now depends on the extended deadline.
Private placement of common stock with aggregate gross proceeds of approximately $24.0 million, before offering expenses, agreed on September 8, 2026
Outside date extended from September 29, 2026 to October 16, 2026 for each purchaser
Company may defer closing until purchaser closing conditions are satisfied or waived, but no later than October 16, 2026, unless otherwise agreed in writing
All other terms of the Purchase Agreement remain unchanged
Indaptus Therapeutics agreed on September 8, 2026 to sell 20,338,974 shares of common stock to purchasers in a private placement for aggregate gross proceeds of about $24.0 million before offering expenses. The company plans to use the proceeds for working capital, research and development, and general corporate purposes, possibly including early-stage work on a neurotechnology device for sleep-related conditions. The shares are unregistered, and the company must later file a resale registration statement, which could add shares to the market.
Shares sold: 20,338,974 shares of common stock at a price equal to the Nasdaq Minimum Price plus $0.015 per share
Gross proceeds: approximately $24.0 million before offering expenses
Closing: subject to customary conditions, no later than the fifteenth business day after September 8, 2026
Shares were sold under Section 4(a)(2) and/or Regulation S and are subject to transfer restrictions
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Indaptus Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →